Literature DB >> 18354253

Is antidepressant treatment associated with reduced cognitive decline in Alzheimer's disease?

Enrico Mossello1, Marta Boncinelli, Veronica Caleri, Maria Chiara Cavallini, Eliana Palermo, Mauro Di Bari, Sabrina Tilli, Eva Sarcone, David Simoni, Carlo Adriano Biagini, Giulio Masotti, Niccolò Marchionni.   

Abstract

BACKGROUND: Although antidepressant drugs (ATD) are frequently prescribed to patients with Alzheimer's disease (AD), their effect on cognitive status has been only rarely assessed.
METHODS: The impact of depressive symptoms and ATD on cognitive status was retrospectively assessed in 72 older AD outpatients with mild-to-moderate cognitive impairment, treated with cholinesterase inhibitors, over a 9-month follow-up.
RESULTS: Compared to subjects without baseline depressive symptoms, those with symptoms who were continuously treated with ATD had less cognitive decline; those never treated, or not continuously treated despite baseline symptoms, had an intermediate trend. Such a protective action of ATD was, at least in part, independent of their action on depressive symptoms.
CONCLUSION: These observations suggest that ATD may reduce cognitive decline in depressed older AD patients. (c) 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18354253     DOI: 10.1159/000121334

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  21 in total

1.  Depressive symptoms, antidepressant use, and future cognitive health in postmenopausal women: the Women's Health Initiative Memory Study.

Authors:  Joseph S Goveas; Patricia E Hogan; Jane M Kotchen; Jordan W Smoller; Natalie L Denburg; JoAnn E Manson; Aruna Tummala; W Jerry Mysiw; Judith K Ockene; Nancy F Woods; Mark A Espeland; Sylvia Wassertheil-Smoller
Journal:  Int Psychogeriatr       Date:  2012-02-03       Impact factor: 3.878

Review 2.  Turning on the Light Within: Subcortical Nuclei of the Isodentritic Core and their Role in Alzheimer's Disease Pathogenesis.

Authors:  Panos Theofilas; Sara Dunlop; Helmut Heinsen; Lea Tenenholz Grinberg
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 3.  Serotonergic system, cognition, and BPSD in Alzheimer's disease.

Authors:  Saikat Chakraborty; Jack C Lennon; Sridhar A Malkaram; Yan Zeng; Daniel W Fisher; Hongxin Dong
Journal:  Neurosci Lett       Date:  2019-04-01       Impact factor: 3.046

Review 4.  [The importance of depressive syndromes for incipient Alzheimer-type dementia in advanced age].

Authors:  M A Rapp; R Hellweg; A Heinz
Journal:  Nervenarzt       Date:  2011-09       Impact factor: 1.214

Review 5.  Impact of Antidepressant Use on the Trajectory of Alzheimer's Disease: Evidence, Mechanisms, and Therapeutic Implications.

Authors:  Rita Khoury; George T Grossberg
Journal:  CNS Drugs       Date:  2019-01       Impact factor: 5.749

6.  Modifiable Midlife Risk Factors for Late-Life Cognitive Impairment and Dementia.

Authors:  Tiffany F Hughes; Mary Ganguli
Journal:  Curr Psychiatry Rev       Date:  2009-05-01

7.  Management of patients with Alzheimer's disease: pharmacological treatment and quality of life.

Authors:  Enrico Mossello; Elena Ballini
Journal:  Ther Adv Chronic Dis       Date:  2012-07       Impact factor: 5.091

8.  Antidepressant Use and Cognitive Outcomes in Very Old Women.

Authors:  Yue Leng; Susan J Diem; Katie L Stone; Kristine Yaffe
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2018-09-11       Impact factor: 6.053

9.  Allosteric modulation of AMPA receptors counteracts Tau-related excitotoxic synaptic signaling and memory deficits in stress- and Aβ-evoked hippocampal pathology.

Authors:  Daniela Monteiro-Fernandes; Joana Margarida Silva; Carina Soares-Cunha; Christina Dalla; Nikolaos Kokras; François Arnaud; Rodolphe Billiras; Viktoriya Zhuravleva; Clarissa Waites; Sylvie Bretin; Nuno Sousa; Ioannis Sotiropoulos
Journal:  Mol Psychiatry       Date:  2020-05-28       Impact factor: 15.992

10.  Efficacy and safety of pharmacotherapy for Alzheimer's disease and for behavioural and psychological symptoms of dementia in older patients with moderate and severe functional impairments: a systematic review of controlled trials.

Authors:  M Seibert; V Mühlbauer; J Holbrook; S Voigt-Radloff; S Brefka; D Dallmeier; M Denkinger; C Schönfeldt-Lecuona; S Klöppel; C A F von Arnim
Journal:  Alzheimers Res Ther       Date:  2021-07-16       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.